Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Next Previous
X
Search
Trial Profile

Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms AtezoTRIBE

    • Most Recent Events

    • 24 Oct 2023 Results assessing the predictive role of immune phenotypes (IPs) and Inflamed Score (IS), as assessed by means of Lunit SCOPE IO, an artificial intelligence (AI)-powered whole-slide images (WSI) analyzer of tumor infiltrating lymphocytes, presented at the 48th European Society for Medical Oncology Congress.
    • 11 Oct 2023 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2023 Results determining the percentage of genomic LOH and the presence of pathogenetic mutations in HRR related genes in archival chemo-naive tumor tissues of mCRC patients included in a real world registry and in the Atezo TRIBE (NCT03721653) and AVETRIC (NCT04513951) studies, presented at the 25th World Congress on Gastrointestinal Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top